BioMarin Pharmaceutical Inc. · NASDAQ:BMRN

BioMarin Pharmaceutical — Jefferies Healthcare Conference 2026

15 slides from BioMarin Pharmaceutical's conference presentation, November 2026

  1. Slide 1: Delivering the next stage of BioMarin’s growth

    Delivering the next stage of BioMarin’s growth Alexander Hardy, President and Chief Executive Officer Brian Mueller, Chief Financial Officer Jefferies Healthcare Conference November 2026

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: future financial performance, including the expecta

  3. Slide 3: BioMarin: Diversified, Global Rare Disease Leader Operating at Scale

    BioMarin: Diversified, Global Rare Disease Leader Operating at Scale Focused on delivering medicines for people living with genetically defined conditions 25+ 9 4 years of rare disease innovation commercial therapies: 6 first-in-disease on-market products with potential to reach $1B+ in annual reven

  4. Slide 4: Three Years of Disciplined Execution Built a Profitable Growth Engine

    Three Years of Disciplined Execution Built a Profitable Growth Engine Growing revenue, earnings per share (EPS), and cash flow enable strategic expansion ANNUAL REVENUE DILUTED EPS OPERATING CASH FLOW GAAP: > 100% ~60% expected growth > 5x increase FY23 to FY26E guidance midpoint Non-GAAP1: > 50% FY

  5. Slide 5: Accelerating Growth with GALAFOLD and POMBILITI + OPFOLDA

    Accelerating Growth with GALAFOLD and POMBILITI + OPFOLDA Amicus Acquisition Expected to be Accretive in First 9 Months Post-close (April 2026) 1 2 Cost Synergies1,2 Expected 3 Peak Revenue Potential Strong Q3’26 Performance to Drive Profitability > $1B Each $201M ~$220M2 $1.4B $1.2B combined GALAFO

  6. Slide 6: Pipeline Expansion Opens Major Market Opportunities

    Pipeline Expansion Opens Major Market Opportunities Four clinical programs with potentially differentiated profiles in large rare disease markets LATE-STAGE | PHASE 3 CLINICAL | PHASE 2/3 CLINICAL | PHASE 1/2a CLINICAL | PHASE 1/2 BMN 820 BMN 333 BMN 440 BMN 450 FSGS1 Achondroplasia (ACH) Hypophosph

  7. Slide 7: Catalyst-rich 2027 Sets Up Next Phase of Growth

    Catalyst-rich 2027 Sets Up Next Phase of Growth Expected data readouts and potential regulatory approvals SKELETAL CONDITIONS BMN 440 (ALE1) Phase 1/2a data for hypophosphatasia (HPP) DATA READOUT 2027 BMN 333 Phase 2 dose-response data for achondroplasia DATA READOUT 2027 VOXZOGO Potential full app

  8. Slide 8: Q&A Thank you

    Q&A Thank you Purpose-Driven. Patient-Focused. Future-Ready.

  9. Slide 9: Appendix

    Appendix Commercial Update Slides from BioMarin’s Third Quarter 2026 Financial Results Presentation As Presented on November 2, 2026

  10. Slide 10: Strong GALAFOLD and POMBILITI + OPFOLDA Patient Growth in Q3’26

    Metabolic GROWTH Conditions Strong GALAFOLD and POMBILITI + OPFOLDA Patient Growth in Q3’26 • +13% Y/Y patient growth • +69% Y/Y patient growth • $152M Q3 revenue • $49M Q3 revenue • Expanded diagnosis and treatment, • Patient switching supported by a with deeper penetration across differentiated cl

  11. Slide 11: Metabolic Conditions: Diversified Portfolio Drove Record Results

    Metabolic GROWTH Conditions Metabolic Conditions: Diversified Portfolio Drove Record Results Metabolic Conditions Q3’26 Revenue Q3’26 Dynamics In millions, except percentages $744M, +44% Y/Y1 • +44% Y/Y revenue growth, driven largely by the first full quarter of GALAFOLD and POMBILITI + OPFOLDA +18%

  12. Slide 12: Skeletal Conditions: Global Growth and Continued Leadership

    Skeletal Conditions Skeletal Conditions: Global Growth and Continued Leadership Revenue Q3’26 Dynamics In millions, except percentages • +12% Y/Y revenue growth; ~17% increase in the number of children treated globally Y/Y • > 75% of revenue generated outside of the U.S. +12% • Large international o

  13. Slide 13: Appendix: Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information

    Appendix Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information

  14. Slide 14: Reconciliation of GAAP Diluted EPS to Non-GAAP Diluted EPS

    Reconciliation of GAAP Diluted EPS to Non-GAAP Diluted EPS(1) (In U.S. dollars) (1) Certain amounts may not sum or recalculate due to rounding. (2) Represents a payment triggered by a third party's attainment of a regulatory approval milestone related to previously sold intangible assets. (3) These

  15. Slide 15: Reconciliation of GAAP Diluted EPS to Non-GAAP Diluted EPS

    Reconciliation of GAAP Diluted EPS to Non-GAAP Diluted EPS(1) (In U.S. dollars) (1) Certain amounts may not sum or recalculate due to rounding. (2) These amounts were included in SG&A and represent severance costs incurred in the acquisition of Inozyme in July 2025. (3) Represents a payment triggere

BioMarin Pharmaceutical — Jefferies Healthcare Conference 2026 on 6ix